Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.17 USD | -2.57% | -10.90% | +36.72% |
Financials (USD)
Sales 2024 * | 68.87M | Sales 2025 * | 102M | Capitalization | 218M |
---|---|---|---|---|---|
Net income 2024 * | -37M | Net income 2025 * | -20M | EV / Sales 2024 * | 3.16 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.14 x |
P/E ratio 2024 * |
-6.26
x | P/E ratio 2025 * |
-14.9
x | Employees | 100 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.28% |
Latest transcript on G1 Therapeutics, Inc.
1 day | -2.57% | ||
1 week | -10.90% | ||
Current month | -3.47% | ||
1 month | +29.91% | ||
3 months | +17.80% | ||
6 months | +223.26% | ||
Current year | +36.72% |
Managers | Title | Age | Since |
---|---|---|---|
Jack Bailey
CEO | Chief Executive Officer | 59 | 20-03-11 |
John Umstead
DFI | Director of Finance/CFO | - | 17-12-31 |
Rajesh K. Malik
CTO | Chief Tech/Sci/R&D Officer | 65 | 14-06-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Glenn Muir
BRD | Director/Board Member | 65 | 15-08-31 |
Cynthia Flowers
BRD | Director/Board Member | 64 | 18-06-06 |
Norman Sharpless
FOU | Founder | 57 | 08-05-18 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.01% | 509 M€ | -.--% | ||
0.01% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 4.17 | -2.57% | 692,556 |
24-04-17 | 4.28 | +4.90% | 690,098 |
24-04-16 | 4.08 | -5.34% | 569,479 |
24-04-15 | 4.31 | -5.27% | 670,488 |
24-04-12 | 4.55 | -2.78% | 563,219 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.72% | 223M | |
-3.30% | 102B | |
+1.79% | 96.84B | |
-0.44% | 21.48B | |
-18.35% | 20.82B | |
-7.45% | 18.6B | |
-40.31% | 16.81B | |
-26.84% | 13.78B | |
+0.59% | 13.4B | |
+20.86% | 11.06B |
- Stock Market
- Equities
- GTHX Stock